We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cue Health Inc | NASDAQ:HLTH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0059 | -8.14% | 0.0666 | 0.0656 | 0.0663 | 0.0801 | 0.06 | 0.0799 | 73,338,370 | 00:59:55 |
Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call.
About Cue Health
Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue’s platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue’s customers include federal and state public sector agencies and the private sector, which includes healthcare providers, enterprises, and individual consumers. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive this FDA approval. Cue also received Emergency Use Authorization from the FDA for its molecular Mpox test at the point-of-care. Cue, founded in 2010, owns over 100 patents and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429794757/en/
Press Cue Health press@cuehealth.com Investors ICR Westwicke Caroline Corner +1-415-202-5678 caroline.corner@westwicke.com
1 Year Cue Health Chart |
1 Month Cue Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions